One participant reached 15 months of disease control
In a University of Minnesota Phase I trial, an experimental genetically engineered adenovirus controlled disease for 15 months in one participant with inoperable pancreatic cancer.
- Field
- gene therapy
- What they did
- Researchers from the University of Minnesota conducted a Phase I clinical trial where three patients with inoperable pancreatic cancer received an injection of a genetically engineered adenovirus.
- Why it matters
- The virus enters and replicates within malignant cells, helping the immune system recognize and attack them, resulting in 15 months of disease control for one participant.
#adenovirus#pancreatic cancer#clinical trial#gene therapy



